Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul;20(7 Suppl 6):8-9.

The Efficacy and Safety of Guselkumab as Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Maintenance Study

No authors listed

The Efficacy and Safety of Guselkumab as Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Maintenance Study

No authors listed. Gastroenterol Hepatol (N Y). 2024 Jul.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Primary endpoint of clinical remission at week 44. Clinical remission was defined as a Mayo stool frequency subscore of 0 or 1 and not increased from baseline, a Mayo rectal bleeding subscore of 0, and Mayo endoscopic subscore of 0 or 1 with no friability present. Randomized full analysis set. 69% of guselkumab-treated patients in clinical remission were also in endoscopic remission (Mayo endoscopic subscore=0). q4w, every 4 weeks; q8w, every 8 weeks; SC, subcutaneous. Adapted from Rubin DT et al. DDW abstract 759. Gastroenterology. 2024;166(6)(suppl 1).
See this image and copyright information in PMC

References

    1. Peyrin-Biroulet L, Allegretti JR, Rubin DT et al. Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction study. Gastroenterology. 2023;165(6):1443–1457. - PubMed
    1. Rubin DT, Allegretti JR, Panés J et al. The efficacy and safety of guselkumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 QUASAR maintenance study [DDW abstract 759]. Gastroenterology. 2024;166(6) suppl 1.
    1. Allegretti JR, Peyrin-Biroulet L, Feagan BG et al. The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 QUASAR induction study [DDW abstract 913b]. Gastroenterology. 2023;164(6):S-1572. suppl. - PMC - PubMed

LinkOut - more resources